Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as Eletriptan commercial tablet
Eletriptan commercial · 1 trial · 1 indication
AUC (0-∞) = Area under the plasma concentration versus time curve (AUC) from time zero (pre-dose) to extrapolated infinite time (0-∞). It is obtained from AUC (0-t) plus AUC (t-∞).
Area under the plasma concentration-time curve from time zero (pre-dose) to the time of the last measurable concentration (AUClast).
| Arm | Type | Description |
|---|---|---|
| Treatment A | EXPERIMENTAL | 1 X 20 mg eletriptan |
| Treatment B | EXPERIMENTAL | 1 X 40 mg eletriptan |
| Treatment C | EXPERIMENTAL | 2 X 40 mg eletriptan |
| Treatment D | EXPERIMENTAL | 1 X 40 mg tablet given 2 hr after initial 1 X 40 mg tablet dose |
| Name | Type | Description |
|---|---|---|
| Eletriptan commercial tablet | DRUG | 20 mg tablet, single dose |
Inclusion Criteria: * healthy male subjects, 18-55 years old * Body Mass Index (BMI) of 17.5 to 30.5 kg/m2 * provide informed consent Exclusion Criteria: * blood pressure \>140/90 mm Hg * any condition possibly affecting drug absorption * positive urine drug screen
Eletriptan commercial is a small molecule drug candidate developed by Pfizer, Inc. under the ticker PFE. It is also known as the Eletriptan commercial tablet. The program is in Phase 1 clinical development, and the specific medical condition it is being studied for has not been disclosed.
Eletriptan commercial targets the serotonin receptors HTR1B, HTR1D, and HTR1F, where it acts as an agonist. By activating these receptor subtypes, the drug is designed to influence serotonin signaling pathways. This target profile places it in the agonist class of small molecule therapeutics.
Eletriptan commercial is being developed by Pfizer, Inc., which trades under the ticker symbol PFE. Pfizer is the sponsor responsible for advancing this small molecule program through clinical testing. The asset is also referred to as the Eletriptan commercial tablet.
Eletriptan commercial is in Phase 1 clinical development. It has not been approved by the FDA and remains an investigational agent. One Phase 1 trial has been completed, and there are currently no active trials listed for this program.
Eletriptan commercial has been evaluated in one completed Phase 1 trial, NCT01139515, titled Eletriptan Pharmacokinetics In Korean Males. The study enrolled 16 healthy male volunteers aged 18 years and older in South Korea. It was a randomized, controlled trial with a pharmacokinetic focus.
Yes, Eletriptan commercial tablet is an alternative name for Eletriptan commercial. Both names refer to the same Pfizer-developed small molecule candidate. The tablet designation reflects the oral dosage form of this Phase 1 asset.